Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells

Min Guan, Lijun Zhu, George Somlo, Alison Hughes, Bingsen Zhou, Yun Yen

研究成果: 雜誌貢獻文章同行評審

7 引文 斯高帕斯(Scopus)

摘要

The ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) has been observed in ∼20% of multiple myeloma (MM) patients. In this study, we investigated whether the therapeutic effect of bortezomib is associated with FGFR3 expression. Materials and Methods: Cell proliferation and apoptosis assays were performed in minimal FGFR3 expressing U266 cells and compared to U266 cells overexpressing FGFR3 wild-type (T-U266), or Y373C (Y-U266) or K650E (K-U266) mutant FGFR3. Results: Our results suggested cell survival decreases in a dose-dependent manner. Interestingly, expression of FGFR3 protein was similarly dose dependent on bortezomib. It is confirmed the bortezomib-induced apoptotic death is correlated with FGFR3 expression. Furthermore, increased expression of p-STAT3, Mcl-1 and VEGF suggested that bortezomib resistance associated with Y373C mutation and wild-type FGFR3 may be partly mediated through p-STAT3 signaling. Conclusion: Our data indicates that Y373C mutation and wild-type FGFR3 may be associated with bortezomib-related treatment resistance in multiple myeloma.

原文英語
頁(從 - 到)1-9
頁數9
期刊Anticancer Research
29
發行號1
出版狀態已發佈 - 一月 1 2009
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells」主題。共同形成了獨特的指紋。

引用此